Type 2 diabetes mellitus (T2DM) is vividly associated with various cardiovascular diseases (CVD) and is a risk factor for heart failure (HF) and renal failure. Mostly, diabetic patients are hospitalized for HF and dialysis. In the year 2008, the USFDA approved four sodium-glucose cotransporters 2 inhibitors (SGLT2i) and from thereon trials to determine the safety and efficacy of these molecules were underway. The benefits of these molecules in patients with cardio-renal diseases were also examined.
Docplexus, in collaboration with the Research Society For The Study Of Diabetes In India, has organized an exclusive Indian Diabetes League 2020 on Cardio-Renal Benefits Are Class Effects Of SGLT2i on the 28th of October, 7:00 PM onwards. Come, be a part of this webinar and get all your queries answered. Stay tuned!
